 The primary objective of the trial is to evaluate the effects of the interruption of a long term treatment ex. Greater than 6 months with Amantadine prescribed as an antidyskinetic in patients suffering from Parkinson disease being treated with Levodopa and suffering from mid dose dyskinesias. 